As­traZeneca's Fasen­ra ex­pands ap­proval in chil­dren with se­vere asth­ma

As­traZeneca’s asth­ma treat­ment Fasen­ra will now be avail­able to younger pa­tients, height­en­ing the com­pe­ti­tion in a crowd­ed field of res­pi­ra­to­ry ri­vals.

The FDA has ex­pand­ed Fasen­ra’s la­bel to in­clude the add-on main­te­nance treat­ment of chil­dren 6 to 11 years old with se­vere eosinophilic asth­ma. The drug was first ap­proved in the 12-years-and-old­er set­ting in 2017.

Fasen­ra is one of a hand­ful of bi­o­log­ics on the US mar­ket to treat se­vere asth­ma, in­clud­ing GSK’s Nu­cala, which beat As­traZeneca to the 6-and-old­er pop­u­la­tion with a la­bel ex­pan­sion in 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.